{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:26:18Z","timestamp":1763036778633,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.revmed.2013.08.004","type":"journal-article","created":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T03:01:45Z","timestamp":1379386905000},"page":"243-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["My\u00e9lome multiple indolent"],"prefix":"10.1016","volume":"35","author":[{"given":"G.","family":"Fouquet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Guidez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Herbaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Demarquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2013.08.004_bib0005","first-page":"211","article-title":"Studies on conditions associated with disturbed gamma globulin formation (gammopathies)","volume":"56","author":"Waldenstrom","year":"1960","journal-title":"Harvey Lect"},{"key":"10.1016\/j.revmed.2013.08.004_bib0010","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2013.08.004_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2013.08.004_bib0020","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (mgus) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2013.08.004_bib0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosinol","year":"2003","journal-title":"Br J Haemtol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0030","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2013.08.004_bib0035","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2013.08.004_bib0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0889-8588(05)70416-0","article-title":"Monoclonal gammopathy of undetermined significance and solitary plasmocytoma. Implications for progression to overt multiple myeloma","volume":"11","author":"Kyle","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.revmed.2013.08.004_bib0045","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1046\/j.1365-2141.1997.4943298.x","article-title":"A population-based registry on paraproteinaemia in the netherlands. Comprehensive cancer centre west, leiden, the netherlands","volume":"99","author":"Ong","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0050","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4065\/mcp.2010.0520","article-title":"Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence","volume":"85","author":"Rajkumar","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.revmed.2013.08.004_bib0055","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when mgus is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2013.08.004_bib0060","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/archinte.1988.00380090051014","article-title":"Prognosis of asymptomatic multiple myeloma","volume":"148","author":"Alexanian","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2013.08.004_bib0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-0609.1991.tb01857.x","article-title":"Incidence and follow-up of asymptomatic multiple myeloma","volume":"47","author":"Wisloff","year":"1991","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0002-9343(93)90120-E","article-title":"Risk of disease progression in asymptomatic multiple myeloma","volume":"94","author":"Dimopoulos","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2013.08.004_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ajh.2830480201","article-title":"Prognostic factors in low tumors mass asymptomatic multiple myeloma: a report on 91\u00a0patients","volume":"48","author":"Facon","year":"1995","journal-title":"Am J Haematol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0080","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1365-2141.1997.1122939.x","article-title":"Prognostic features of asymptomatic multiple myeloma","volume":"97","author":"Weber","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0085","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0090","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0095","first-page":"687a","article-title":"Abnormal mri of spine is the dominant risk factor for early progression of asymptomatic multiple myeloma","volume":"102","author":"Wang","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2013.08.004_bib0100","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0105","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2013.08.004_bib0110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2013.08.004_bib0115","first-page":"1655","article-title":"Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between mgus and multiple myeloma","volume":"152","author":"Ocqueteau","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0120","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (mgus) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2013.08.004_bib0125","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","article-title":"Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations","volume":"28","author":"Blade","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage i: a randomized study. Myeloma group of western sweden","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0135","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage i multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative group of study and treatment of multiple myeloma","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.revmed.2013.08.004_bib0140","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ajh.21821","article-title":"Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma","volume":"85","author":"Detweiler-Short","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2013.08.004_bib0145","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2013.08.004_bib0150","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","author":"D\u2019Arena","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.revmed.2013.08.004_bib0155","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866313006279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866313006279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:32:13Z","timestamp":1759336333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866313006279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0248866313006279"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2013.08.004","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"My\u00e9lome multiple indolent","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2013.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}